- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Guardant Health Inc(GH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GH
11/13/2026: GH (5-star) is currently NOT-A-BUY. Pass it for now.
Guardant Health Inc is a commercial-stage precision oncology company specializing in non-invasive blood-based cancer diagnostics and screening. Its primary strengths lie in its proprietary liquid biopsy technology, led by tests like Guardant360 and the FDA-approved Shield colorectal screening test, which deliver solid gross margins and robust revenue growth. The core investment opportunity rests on capturing a massive primary care market through accessible cancer screening. However, key risks include ongoing net losses, heavy reliance on reimbursement payors, and intense competition from rivals. The stock suits growth-oriented investors willing to monitor regulatory updates, reimbursement milestones, and progress toward profitability.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Rapid top-line revenue expansion and massive addressable markets in cancer screening align well with growth strategies. |
| Momentum investor | Strong fit while signal remains positive | Strong quarterly volume reports and raising guidance can spark sharp positive momentum shifts. |
| Value investor | Weak fit | The company currently reports net losses and trades on forward growth potential rather than traditional value metrics. |
| Dividend investor | Weak fit | Guardant Health does not pay dividends, retaining all earnings for business reinvestment. |
| Low-risk investor | Weak fit | High volatility and unprofitability present execution and regulatory risks unsuited for low-risk profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech and diagnostic stocks frequently experience sharp price swings based on clinical data releases and reimbursement news. |
| Valuation risk | Medium / high | Valuations heavily discount future cash flows from emerging screening products, leaving little room for commercial execution errors. |
| Competition risk (Exact Sciences, Natera, Tempus AI) | High | Aggressive rivals are scaling rival screening, MRD, and tumor profiling platforms that could capture market share. |
| Business quality | Strong | The company possesses high gross margins and proprietary technology protecting its core liquid biopsy franchise. |
| Dividend income | Low / none | No dividends are distributed as cash is prioritized for R&D and commercial scaling. |
| Execution risk | High | Successfully scaling primary care adoption for Shield requires overcoming entrenched screening habits and securing broad insurance coverage. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 20.52B USD | Price to earnings Ratio - | 1Y Target Price 200.76 |
Price to earnings Ratio - | 1Y Target Price 200.76 | ||
Volume (30-day avg) 2.1M shares | Beta 1.66 | 52 Weeks Range 74.55 - 191.05 | Updated Date 11/15/2026 |
52 Weeks Range 74.55 - 191.05 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.68 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Diagnostics & Research
- BUY participation
- 68.8%
- Active BUY / eligible
- 11 / 16
- 30-Day BUY Count Change
- 0
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 66.48% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Tests | Revenues generated from processing Guardant360, Guardant Reveal, and Shield tests ordered by physicians for patient care. | This is the core engine of the company, bringing in the vast majority of revenue as more doctors adopt blood-based testing. |
| Development Services | Collaborations with biopharmaceutical companies to support clinical trials and companion diagnostic development. | Provides stable partnership revenue and helps validate technologies alongside major drug launches. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21.21B | Price to Sales(TTM) 16.05 |
Enterprise Value 21.21B | Price to Sales(TTM) 16.05 | ||
Enterprise Value to Revenue 16.58 | Enterprise Value to EBITDA -5.4 | Shares Outstanding 135.29M | Shares Floating 130.57M |
Shares Outstanding 135.29M | Shares Floating 130.57M | ||
Percent Insiders 4.65 | Percent Institutions 98.73 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

